Phase 3 trial using the SYK inhibitor, entospletinib, in combination with standard induction and consolidation chemotherapy in newly diagnosed, NPM1 mutated Acute Myelogenous Leukemia
For more information about the trial above please contact the study team:
Principal Investigator, Praneeth Baratam, at email@example.com.
Study Coordinator, Sarah Britton, at firstname.lastname@example.org, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina